Takashi Koizumi

Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide.

Hideki Ohnota, Takashi Koizumi, Naoyuki Tsutsumi et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 62 citations

Medicine, Medicinal Chemistry, Pharmacology +9

Genotype–phenotype correlations and effect of mutation location in Japanese CADASIL patients

Mao Mukai, Ikuko Mizuta, Akiko Watanabe-Hosomi et al. · Journal of Human Genetics · 2020 · 47 citations

Life Sciences, Genetics, Molecular Genetics +16

Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes

S-I. Harashima, Mariko Ogura, Daisuke Tanaka et al. · International Journal of Clinical Practice · 2012 · 45 citations

Medicine, Endocrinology, Pharmacology +13

New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy in Japan

Ikuko Mizuta, Akiko Watanabe-Hosomi, Takashi Koizumi et al. · Journal of the Neurological Sciences · 2017 · 37 citations · Full text

Life Sciences, Genetics, Neurology +17

Chronic kidney disease, 24-h blood pressure and small vessel diseases are independently associated with cognitive impairment in lacunar infarct patients

Yasumasa Yamamoto, Tomoyuki Ohara, Yoshinari Nagakane et al. · Hypertension Research · 2011 · 34 citations · Full text

Medicine, Nephrology, Neurology +17